Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Post by scarlet1967on Jun 23, 2021 1:51pm
118 Views
Post# 33435172

Volume

Volume Daily volume is rising, I hope it's not transitory so investors/traders can get in without feeling trapped in case they want to buy the shares even for short term gains. We had two PRs this week and the webinar so to me that's the reason for increasing demand. I certainly hope the company keep coming up with good news every week but that's not realistic so they should keep reminding the market periodically on what they have achieved so far until next meaningful news. The valuation discrepancies in today's environment should be addressed based on the new normal which is feeding also the retail investors with what they need to actively follow this company, by all means try to get as many institutions interested but the old golden rule "Market is always right" might not be as relevant as it was. The market has now two equal segments each can push valuations, the retail is less sophisticated easier to convince and they are out there supporting many companies valuation even so they might be involved with bogus companies so getting their attention is a  must to do in order to be competitive in this market. The analysts are not interested in thin equities as their customers and general retail investors (their potential future clients) want to be involved with trendy companies, get those folks attention the analysts will follow and start covering the company. 
<< Previous
Bullboard Posts
Next >>